Clovis Oncology Inc. [CLVS] stock Reiterated by H.C. Wainwright analyst, price target now $33

Related

Share

Clovis Oncology Inc. [NASDAQ: CLVS] traded at a high on 01/11/22, posting a 5.41 gain after which it closed the day’ session at $2.73. The company report on January 10, 2022 that Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021.

Estimated $35.5M – $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M – $148.9M for FY 2021.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Continuing impact on ovarian cancer diagnoses and treatments from COVID-19.

The results of the trading session contributed to over 3924639 shares changing hands. Over the past one week, the price volatility of Clovis Oncology Inc. stands at 9.21% while the volatility over the past one month is 9.11%.

The market cap for CLVS stock reached $377.07 million, with 129.98 million shares outstanding and 128.04 million shares in the current float. Compared to the average trading volume of 3.52M shares, CLVS reached a trading volume of 3924639 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Clovis Oncology Inc. [CLVS]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $6.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.

The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.25, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 2.42.

How has CLVS stock performed recently?

Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.19. With this latest performance, CLVS shares dropped by -1.44% in over the last four-week period, additionally sinking by -48.39% over the last 6 months – not to mention a drop of -54.27% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 44.21, with the RSI for the last a single of trading hit 45.81, and the three-weeks RSI is set at 43.03 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 3.29, while it was recorded at 2.65 for the last single week of trading, and 4.74 for the last 200 days.

Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -183.68 and a Gross Margin at +74.89. Clovis Oncology Inc.’s Net Margin is presently recorded at -224.41.

Return on Total Capital for CLVS is now -58.76, given the latest momentum, and Return on Invested Capital for the company is -77.43. Additionally, CLVS Total Debt to Total Capital is recorded at 132.52, with Total Debt to Total Assets ending up at 105.60.

Reflecting on the efficiency of the workforce at the company, Clovis Oncology Inc. [CLVS] managed to generate an average of -$860,634 per employee. Receivables Turnover for the company is 5.04 with a Total Asset Turnover recorded at a value of 0.26.Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.00.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Clovis Oncology Inc. [CLVS]

There are presently around $169 million, or 48.60% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 14,674,754, which is approximately 47.982% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 12,294,891 shares of the stock with an approximate value of $33.56 million in CLVS stocks shares; and BLACKROCK INC., currently with $25.92 million in CLVS stock with ownership of nearly 7.707% of the company’s market capitalization.

Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 82 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 11,059,333 shares. Additionally, 60 investors decreased positions by around 4,694,449 shares, while 39 investors held positions by with 46,020,042 shares. The mentioned changes placed institutional holdings at 61,773,824 shares, according to the latest SEC report filing. CLVS stock had 24 new institutional investments in for a total of 763,932 shares, while 24 institutional investors sold positions of 1,362,316 shares during the same period.